Real-World Prevalence of PD-L1 Expression in Chinese Patients with Advanced or Metastatic NSCLC: Express II Study

被引：0
|
作者：
Lin, D. [1 ]
Yang, X. [1 ]
Jiang, L. [2 ]
Wang, W. [2 ]
Hou, Y. [3 ]
Li, Y. [4 ]
Jin, Y. [4 ]
Fan, X. [5 ]
Sun, W. [6 ]
Yun, J. [7 ]
Li, P. [7 ]
Kuang, D. [8 ]
Zhang, L. [9 ]
Ni, J. [10 ]
Mao, A. [11 ]
Tang, W. [11 ]
Liu, Z. [11 ]
Wang, J. [11 ]
Xiao, S. [11 ]
机构：
[1] Beijing Canc Hosp, Beijing, Peoples R China
[2] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[3] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[4] Fudan Univ, Shanghai Med Coll, Dept Pathol, Shanghai, Peoples R China
[5] Nanjing Drum Tower Hosp, Nanjing, Peoples R China
[6] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
[7] Sun Yat Sen, Canc Hosp, Guangzhou, Peoples R China
[8] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Shanghai, Peoples R China
[9] Shanghai Pulm Hosp, Shanghai, Peoples R China
[10] First Hosp Jilin Univ, Eastern Div, Changchun, Peoples R China
[11] Bldg A,Headquarters Pk Phase 2,1582 Gumei Rd, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
Non-small cell lung cancer; programmed death-ligand 1; IHC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P33.12
引用
收藏
页码：S410 / S410
页数：1
相关论文
共 50 条
  • [31] Real-world evaluation of pembrolizumab monotherapy for previously treated PD-L1 positive (TPS>1%) advanced NSCLC in France
    Perol, M.
    Quantin, X.
    Lena, H.
    Filleron, T.
    Chouaid, C.
    Valette, C. Audigier
    Kaderbhai, C.
    Chenuc, G.
    Santorelli, M.
    Bensimon, L.
    Burke, T.
    Simon, G.
    Martin, A-L.
    Debieuvre, D.
    Gervais, R.
    Schott, R.
    Carton, M.
    Courtinard, C.
    Girard, N.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S758 - S758
  • [32] Analysis of real-world PD-L1 testing in patients with urothelial carcinoma.
    Krigsfeld, Gabriel S.
    Prince, Emily
    Zerba, Kim
    Chizhevsky, Vladislav
    Ragheb, Josette William
    Novotny, James
    White, James William
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [33] Pembrolizumab frontline monotherapy in patients with NSCLC and high PD-L1 expression: Real-world data from a European Cohort with focus on subgroups of interest
    Mountzios, G.
    Signorelli, D.
    Cobo, J. Rey
    Banini, M.
    Economopoulou, P.
    Lo Russo, G.
    Baxevanos, P. T.
    Roila, F.
    de Toma, A.
    Banna, G.
    Christopoulou, A.
    Jimenez, B.
    Linardou, H.
    Calles, A.
    Galetta, D.
    Addeo, A.
    Camerini, A.
    Kosmidis, P. A.
    Garassino, M. C.
    Metro, G.
    ANNALS OF ONCOLOGY, 2019, 30
  • [34] Radiotherapy and PD-L1 inhibition in metastatic NSCLC
    De Ruysscher, Dirk
    LANCET ONCOLOGY, 2017, 18 (07): : 840 - 842
  • [35] Association of PD-L1 expression with efficacy of alectinib in advanced NSCLC patients with ALK fusion
    Pan, Yingying
    Liu, Xinyu
    Zhang, Wei
    Wang, Wanying
    Wang, Haowei
    Luo, Libo
    Jia, Keyi
    Shao, Chuchu
    Mao, Shiqi
    Qiu, Tianyu
    Ni, Jun
    Yu, Jia
    Wang, Lei
    Chen, Bin
    Xiong, Anwen
    Gao, Guanghui
    Chen, Xiaoxia
    Wu, Fengying
    Zhou, Caicun
    Wu, Chunyan
    Ren, Shengxiang
    LUNG CANCER, 2023, 181
  • [36] Real-World Prevalence of PD-L1 Expression Among Tumor Samples From Patients With Non-Small-Cell Lung Cancer
    Gelatti, Ana C. Z.
    Cordeiro de Lima, Vladmir C.
    Freitas, Helano
    Werutsky, Gustavo
    Gaiger, Ana Maria
    Klock, Clovis
    Viola, Patricia P.
    Shiang, Christina
    de Macedo, Mariana P.
    Lopes, Lisandro F.
    De Marchi, Pedro
    Albino da Silva, Eduardo Caetano
    Moura, Fernando
    Borges, Giuliano
    Zaffaroni, Facundo
    Nunes Filho, Paulo Ricardo
    Araujo, Luiz H.
    Mascarenhas, Eldsamira
    Mathias, Clarissa
    Barrios, Carlos
    Zukin, Mauro
    CLINICAL LUNG CANCER, 2020, 21 (06) : E511 - E515
  • [37] Evaluating tumor inflammation and PD-L1 expression in sequential biopsies of real-world primary and metastatic breast cancer.
    Wallen, Zachary D.
    Pabla, Sarabjot
    Nesline, Mary K.
    Gao, Shuang
    Vanroey, Erik
    DePietro, Paul
    Conroy, Jeffrey M.
    Ko, Heidi Chwan
    Strickland, Kyle C.
    Previs, Rebecca A.
    Hastings, Stephanie B.
    Eisenberg, Marcia
    Caveney, Brian
    Severson, Eric A.
    Ramkissoon, Shakti H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States
    Velcheti, Vamsidhar
    Patwardhan, Pallavi D.
    Liu, Frank Xiaoqing
    Chen, Xin
    Cao, Xiting
    Burke, Thomas
    PLOS ONE, 2018, 13 (11):
  • [39] Real-World PD-L1 Expression in Lung Cancer and its Correlation with Driver Mutations
    Wang, T.
    Xiao, S.
    Zhao, L.
    Chai, T.
    Fang, X.
    Lin, R.
    Li, T.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S452 - S452
  • [40] PD-L1 expression in advanced NSCLC: Primary lesions versus metastatic sites and impact of sample age
    Midha, Anita
    Sharpe, Alan
    Scott, Marietta
    Walker, Jill
    Shi, Kunyang
    Ballas, Marc
    Garassino, Marina C.
    Rizvi, Naiyer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345